<DOC>
	<DOCNO>NCT01242904</DOCNO>
	<brief_summary>Peritoneal dialysis ( PD ) method renal replacement therapy use close 200,000 end stage renal disease patient worldwide help replace function long perform kidney . An important advantage PD offer alternative hemodialysis safely perform patient home . In PD , peritoneal membrane line abdomen act dialyzer allows transfer solute water membrane capillary dialysis solution infuse peritoneal cavity . PD dialysis solution typically require high concentration glucose adequately perform function . Over time continue exposure peritoneal membrane high concentration glucose permanently damage membrane . Icodextrin polyglucose molecule develop use PD solution harm peritoneal membrane . However , use lead inadequate fluid removal . Recent research focus find PD solution , combination solution , maximize removal toxic substance metabolites maintain regulation fluid electrolyte balance body . A bimodal solution combine glucose icodextrin show observational study effective safe . The investigator propose randomize , control , blind study determine effectiveness safety bimodal fluid Canadian PD population . The investigator hypothesize use bimodal solution long ( day ) dwell lead improvement 24 hour ultrafiltration efficiency compare usual care use icodextrin long dwell .</brief_summary>
	<brief_title>Use Bimodal Solution Peritoneal Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Icodextrin</mesh_term>
	<criteria>1 . Be able provide inform consent 2 . Age great 18 year 3 . Be stable Automated Peritoneal Dialysis ( APD ) patient least 6 week 4 . Be APD patient ; 1 . Can manage icodextrin long dwell AND 2 . Will use 4.25 % and/or 2.5 % solution least one exchange overnight least 5 7 day 5 . Have residual urine volume &lt; 800 ml/24 hour 6 . Long dwell must patient must tolerate least 810 hr long dwell . 1 . Scheduled Transplant next 1 year 2 . Life expectancy &lt; 3 mo ( estimate physician ) 3 . Participating trial could influence outcome trial 4 . Known icodextrin allergy 5 . Currently use nonBaxter PD solution 6 . Systolic blood pressure &lt; 90 mm Hg three occasion seven day period , despite discontinuation nonessential antihypertensive Supplementary Exclusion Criteria ( post Runin phase ) : 1 ) Unsuccessfully complete 1 week runin phase . Defined : 1 . Not use bimodal solution 7 consecutive day runin 2 . Not tolerate increase UF anticipate bimodal solution . Tolerating define : ) Blood pressure drop 90/50 three occasion seven day period correct reduce antihypertensive simple measure ii ) Intolerable feel fullness bimodal solution iii ) Allergic reaction ( although patient already expose icodextrin )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>dialysis solution</keyword>
	<keyword>renal replacement therapy</keyword>
	<keyword>peritoneal dialysis</keyword>
	<keyword>bimodal solution</keyword>
	<keyword>glucose spar therapy</keyword>
</DOC>